Randomized, controlled trial of clonidine for smoking cessation in a primary care setting

Peter Franks, J. Harp, B. Bell

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Clonidine hydrochloride has been reported to reduce tobacco withdrawal symptoms and facilitate smoking cessation. We enrolled 185 subjects, 92 receiving clonidine and 93 receiving placebo, in a randomized, double-blind study of clonidine for smoking cessation in a primary care setting. Clonidine had no demonstrable effect on withdrawal (8 of 11 measures favoring placebo). At 4 weeks, 17 (18%) subjects receiving clonidine had quit compared with 13 (14%) receiving placebo (χ2 = 0.7; 90% confidence interval of benefit from clonidine, -4% to 13%). At 4 weeks, the mean number of cigarettes smoked was 17.7 for those receiving clonidine and 17.5 for those receiving placebo (t = 0.1; 90% confidence interval of benefit from clonidine, -4.1 to 3.7 cigarettes per day). These results provide little support for a beneficial effect of clonidine on tobacco withdrawal symptoms, quitting, or smoking reduction in a primary care setting.

Original languageEnglish (US)
Pages (from-to)3011-3013
Number of pages3
JournalJournal of the American Medical Association
Volume262
Issue number21
DOIs
StatePublished - 1989
Externally publishedYes

Fingerprint

Clonidine
Smoking Cessation
Primary Health Care
Randomized Controlled Trials
Placebos
Substance Withdrawal Syndrome
Tobacco Products
Tobacco
Confidence Intervals
Double-Blind Method
Smoking

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Randomized, controlled trial of clonidine for smoking cessation in a primary care setting. / Franks, Peter; Harp, J.; Bell, B.

In: Journal of the American Medical Association, Vol. 262, No. 21, 1989, p. 3011-3013.

Research output: Contribution to journalArticle

@article{a583ecea01bd4664a8475fb3f30e0c55,
title = "Randomized, controlled trial of clonidine for smoking cessation in a primary care setting",
abstract = "Clonidine hydrochloride has been reported to reduce tobacco withdrawal symptoms and facilitate smoking cessation. We enrolled 185 subjects, 92 receiving clonidine and 93 receiving placebo, in a randomized, double-blind study of clonidine for smoking cessation in a primary care setting. Clonidine had no demonstrable effect on withdrawal (8 of 11 measures favoring placebo). At 4 weeks, 17 (18{\%}) subjects receiving clonidine had quit compared with 13 (14{\%}) receiving placebo (χ2 = 0.7; 90{\%} confidence interval of benefit from clonidine, -4{\%} to 13{\%}). At 4 weeks, the mean number of cigarettes smoked was 17.7 for those receiving clonidine and 17.5 for those receiving placebo (t = 0.1; 90{\%} confidence interval of benefit from clonidine, -4.1 to 3.7 cigarettes per day). These results provide little support for a beneficial effect of clonidine on tobacco withdrawal symptoms, quitting, or smoking reduction in a primary care setting.",
author = "Peter Franks and J. Harp and B. Bell",
year = "1989",
doi = "10.1001/jama.262.21.3011",
language = "English (US)",
volume = "262",
pages = "3011--3013",
journal = "JAMA - Journal of the American Medical Association",
issn = "0002-9955",
publisher = "American Medical Association",
number = "21",

}

TY - JOUR

T1 - Randomized, controlled trial of clonidine for smoking cessation in a primary care setting

AU - Franks, Peter

AU - Harp, J.

AU - Bell, B.

PY - 1989

Y1 - 1989

N2 - Clonidine hydrochloride has been reported to reduce tobacco withdrawal symptoms and facilitate smoking cessation. We enrolled 185 subjects, 92 receiving clonidine and 93 receiving placebo, in a randomized, double-blind study of clonidine for smoking cessation in a primary care setting. Clonidine had no demonstrable effect on withdrawal (8 of 11 measures favoring placebo). At 4 weeks, 17 (18%) subjects receiving clonidine had quit compared with 13 (14%) receiving placebo (χ2 = 0.7; 90% confidence interval of benefit from clonidine, -4% to 13%). At 4 weeks, the mean number of cigarettes smoked was 17.7 for those receiving clonidine and 17.5 for those receiving placebo (t = 0.1; 90% confidence interval of benefit from clonidine, -4.1 to 3.7 cigarettes per day). These results provide little support for a beneficial effect of clonidine on tobacco withdrawal symptoms, quitting, or smoking reduction in a primary care setting.

AB - Clonidine hydrochloride has been reported to reduce tobacco withdrawal symptoms and facilitate smoking cessation. We enrolled 185 subjects, 92 receiving clonidine and 93 receiving placebo, in a randomized, double-blind study of clonidine for smoking cessation in a primary care setting. Clonidine had no demonstrable effect on withdrawal (8 of 11 measures favoring placebo). At 4 weeks, 17 (18%) subjects receiving clonidine had quit compared with 13 (14%) receiving placebo (χ2 = 0.7; 90% confidence interval of benefit from clonidine, -4% to 13%). At 4 weeks, the mean number of cigarettes smoked was 17.7 for those receiving clonidine and 17.5 for those receiving placebo (t = 0.1; 90% confidence interval of benefit from clonidine, -4.1 to 3.7 cigarettes per day). These results provide little support for a beneficial effect of clonidine on tobacco withdrawal symptoms, quitting, or smoking reduction in a primary care setting.

UR - http://www.scopus.com/inward/record.url?scp=0024398362&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024398362&partnerID=8YFLogxK

U2 - 10.1001/jama.262.21.3011

DO - 10.1001/jama.262.21.3011

M3 - Article

C2 - 2681856

AN - SCOPUS:0024398362

VL - 262

SP - 3011

EP - 3013

JO - JAMA - Journal of the American Medical Association

JF - JAMA - Journal of the American Medical Association

SN - 0002-9955

IS - 21

ER -